The binding sites for competitive antagonistic, allosteric antagonistic, and agonistic antibodies to the I domain of integrin LFA-1

Journal of Immunology

Volumn 173, Issue 6, 2004, Pages 3972-3978

  Lu, Chafen ^a   Shimaoka, Motomu ^a   Salas, Azucena ^a   Springer, Timothy A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; DIMER; EPITOPE; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; LIGAND; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MONOCLONAL ANTIBODY; PHENYLALANINE;

ALLOSTERISM; ALPHA HELIX; ANTIGEN ANTIBODY REACTION; ARTICLE; BINDING AFFINITY; BINDING SITE; COMPETITIVE INHIBITION; CRYSTAL STRUCTURE; HUMAN; HUMAN CELL; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN;

EID: 4644342292     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.173.6.3972     Document Type: Article

References (46)

1. Larson, R. S., and T. A. Springer. 1990. Structure and function of leukocyte integrins. Immunol. Rev. 114:181.
2. 2-integrins and their cellular ligands. Eur. J. Biochem. 245:215.
3. Carman, C. V., and T. A. Springer. 2003. Integrin avidity regulation: are changes in affinity and conformation underemphasized? Curr. Opin. Cell Biol. 15:547.
4. Shimaoka, M., J. Takagi, and T. A. Springer. 2002. Conformational regulation of integrin structure and function. Annu. Rev. Biophys. Biomol. Struct. 31:485.
5. Emsley, J., C. G. Knight, R. W. Farndale, M. J. Barnes, and R. C. Liddington. 2000. Structural basis of collagen recognition by integrin α2β1. Cell 101:47.
6. L I domain and its complex with ICAM-1 reveal a shape-shifting pathway for integrin regulation. Cell 112:99.
7. 2 is sufficient for strong adhesive function when locked in the open conformation with a disulfide. Proc. Natl. Acad. Sci. USA 98:2387.
8. L I domains with high affinity and antagonist activity in vivo. Proc. Natl. Acad. Sci. USA 98:6009.
9. Labadia, M. E., D. D. Jeanfavre, G. O. Caviness, and M. M. Morelock. 1998. Molecular regulation of the interaction between leukocyte function-associated antigen-1 and soluble ICAM-1 by divalent metal cations. J. Immunol. 161:836.
10. 2) integrin. Proc. Natl. Acad. Sci. USA 92:10277.
11. Qu, A., and D. J. Leahy. 1996. The role of the divalent cation in the structure of the I domain from the CD11a/CD18 integrin. Structure 4:931.
12. Kallen, J., K. Welzenbach, P. Ramage, D. Geyl, R. Kriwacki, G. Legge, S. Cottens, G. Weitz-Schmidt, and U. Hommel. 1999. Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain. J. Mol. Biol. 292:1.
13. Legge, G. B., R. W. Kriwacki, J. Chung, U. Hommel, P. Ramage, D. A. Case, H. J. Dyson, and P. E. Wright. 2000. NMR solution structure of the inserted domain of human leukocyte function associated antigen-1. J. Mol. Biol. 295:1251.
14. Huang, C., and T. A. Springer. 1995. A binding interface on the I domain of lymphocyte function associated antigen-1 (LFA-1) required for specific interaction with intercellular adhesion molecule 1 (ICAM-1) J. Biol. Chem. 270:19008.
15. Huang, C., and T. A. Springer. 1995. Domain localization and correlation with inhibition of function of workshop CD11a mAb. In Leucocyte Typing V: White Cell Differentiation Antigens. S. F. Schlossman, L. Bournsell, W. Gilks, J. Harlan, T. Kishimoto, T. Morimoto, J. Ritz, S. Shaw, R. Silverstein, T. Springer, T. Tedder, and R. Todd, eds. Oxford Univ. Press, New York, p, 1595.
16. Huang, C., Q. Zang, J. Takagi, and T. A. Springer. 2000. Structural and functional studies with antibodies to the integrin β2 subunit: a model for the I-like domain. J. Biol. Chem. 275:21514.
17. Landis, R. C., R. I. Bennett, and N. Hogg. 1993. A novel LFA-1 activation epitope maps to the I domain. J. Cell Biol. 120:1519.
18. 2 I domain with disulfide bonds reveals functional relationships among integrin domains. Proc. Natl. Acad. Sci. USA 98:2393.
19. Bazil, V., I. Stefanova, I. Hilgert, H. Kristofova, S. Vanek, and V. Horejsi. 1990. Monoclonal antibodies against human leucocyte antigens. IV. Antibodies against subunits of the LFA-1 (CD11a/CD18) leucocyte-adhesion glycoprotein. Folia Biol. (Praha) 36:41.
20. Fischer, A., W. Friedrich, A. Fasth, S. Blanche, F. Le Deist, D. Girault, F. Veber, J. Vossen, M. Lopez, C. Griscelli, and M. Hirn. 1991. Reduction of graft failure by a monoclonal antibody (anti-LFA-1 CD11a) after HLA nonidentical bone marrow transplantation in children with immunodeficiencies, osteopetrosis, and Fanconi's anemia: a European group for immunodeficiency/European group for bone marrow transplantation report, Blood 77:249.
21. Gordon, K. B., K. A. Papp, T. K. Hamilton, P. A. Walicke, W. Dummer, N. Li, B. W. Bresnahan, and A. Menter. 2003. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. J. Am. Med. Assoc. 290:3073.
22. Sanchez-Madrid, F., A. M. Krensky, C. F. Ware, E. Robbins, J. L. Strominger, S. J. Burakoff, and T. A. Springer. 1982. Three distinct antigens associated with human T lymphocyte-mediated cytolysis: LFA-1, LFA-2, and LFA-3. Proc. Natl. Acad. Sci. USA 79:7489.
23. Ohashi, Y., S. Tsuchiya, H. Fujie, M. Minegishi, and T. Konno. 1992. Anti-LFA-1 antibody treatment of a patient with steroid-resistant severe graft-versus-host disease. J. Exp. Med. 167:297.
24. Fischer, A., S. Blanche, F. Veber, M. Delaage, C. Mawas, C. Griscelli, F. Le Deist, M. Lopez, D. Olive, and G. Janossy. 1986. Prevention of graft failure by an anti-HLFA-1 monoclonal antibody in HLA-mismatched bone-marrow transplantation. Lancet 2:1058.
25. Petruzzelli, L., J. Luk, and T. A. Springer. 1995. Adhesion structure subpanel 5, leukocyte integrins: CD11a, CD11b, CD11c, CD18. In Leucocyte Typing V: White Cell Differentiation Antigens. S. F. Schlossman, L. Boumsell, W. Gilks, J. Harlan, T. Kishimoto, T. Morimoto, J. Ritz, S. Shaw, R. Silverstein, T. Springer, T. Tedder, and R. Todd, eds. Oxford Univ. Press, New York, p. 1581.
26. Springer, T. A., E. Luther, and L. B. Klickstein. 1995. Adhesion structures: section report. In Leukocyte Typing V: White Cell Differentiation Antigens. S. F. Schlossman, L. Boumsell, W. Gilks, J. Harlan, T. Kishimoto, T. Morimoto, J. Ritz, S. Shaw, R. Silverstein, T. Springer, T. Tedder, and R. Todd, eds. Oxford University Press, New York, p. 1443.
27. Ho, S. N., H. D. Hunt, R. M. Horton, J. K. Pullen, and L. R. Pease. 1989. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77:51.
28. Horton, R. M., Z. Cai, S. N. Ho, and L. R. Pease. 1990. Gene splicing by overlap extension: tailor-made genes using the polymerase chain reaction. BioTechniques 8:528.
29. 2 subunit reveals regions that become exposed upon receptor activation. J. Immunol. 166:5629.
30. 2 subunit. Proc. Natl. Acad. Sci. USA 94:3162.
31. Champe, M., B. W. McIntyre, and P. W. Berman. 1995. Monoclonal antibodies that block the activity of leukocyte function-associated antigen 1 recognize three discrete epitopes in the inserted domain of CD11a. J. BioL. Chem. 270:1388.
32. Hildreth, J. E. K., F. M. Gotch, P. D. K. Hildreth, and A. J. McMichael. 1983. A human lymphocyte-associated antigen involved in cell-mediated lympholysis. Eur. J. Immunol. 13:202.
33. Gottlieb, A. B., J. G. Krueger, K. Wittkowski, R. Dedrick, P. A. Walicke, and M. Garovoy. 2002. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch. Dermatol. 138:591.
34. Lo Conte, L., C. Chothia, and J. Janin. 1999. The atomic structure of protein-protein recognition sites. J. Mol. Biol. 285:2177.
35. Sanchez-Madrid, F., D. Davignon, E. Martz, and T. A. Springer. 1982. Antigens involved in mouse cytolytic T-lymphocyte (CTL)-mediated killing: functional screening and topographic relationship. Cell. Immunol. 73:1.
36. Trowbridge, I. S., and M. B. Omary. 1981. Molecular complexity of leukocyte surface glycoproteins related to the macrophage differentiation antigen Mac-1. J. Exp. Med. 154:1517.
37. Harning, R., J. Pelletier, K. Lubbe, F. Takei, and V. J. Merluzzi. 1991. Reduction in the severity of graft-versus-host disease and increased survival in allogeneic mice by treatment with monoclonal antibodies to cell adhesion antigens LFA-1α and MALA-2. Transplantation 52:842.
38. Gadek, T. R., D. J. Burdick, R. S. McDowell, M. S. Stanley, J. C. Marsters, Jr., K. J. Paris, D. A. Oare, M. E. Reynolds, C. Ladner, K. A. Zioncheck, et al. 2002. Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory epitope to a small molecule. Science 295:1086.
39. Yang, W., M. Shimaoka, J. F. Chen, and T. A. Springer. 2004. Activation of integrin β subunit I-like domains by one-turn C-terminal α-helix deletions. Proc. Natl. Acad. Sci. USA 101:2333.
40. Oxvig, C., C. Lu, and T. A. Springer. 1999. Conformational changes in tertiary structure near the ligand binding site of an integrin I domain. Proc. Natl. Acad. Sci. USA 96:2215.
41. Huth, J. R., E. T. Olejniczak, R. Mendoza, H. Liang, E. A. Harris, M. L. Lupher, Jr., A. E. Wilson, S. W. Fesik, and D. E. Staunton. 2000. NMR and mutagenesis evidence for an I domain allosteric site that regulates lymphocyte function-associated antigen 1 ligand binding. Proc. Natl. Acad. Sci. USA 97:5231.
42. 2 (Mac-1) critical for specific recognition of C3bi. Biochemistry 38:8064.
43. A domain? Curr. Biol. 12:R340.
44. Nicholls, A., K. A. Sharp, and B. Honig. 1991. Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins 11:281.
45. Esnouf, R. M. 1997. An extensively modified version of MolScript that includes greatly enhanced coloring capabilities. J. Mol. Graph. Model. 15:132.
46. Merritt, E. A., and M. E. P. Murphy. 1994. Raster 3D version 2.0: a program for photorealistic graphics. Acta Crystallogr. D 50:869.